Table 2Characteristics of Included Systematic Reviews and Meta-Analyses

First Author, Publication Year, CountryStudy Designs and Numbers of Primary Studies IncludedPopulation CharacteristicsIntervention, ComparatorClinical Outcomes, Length of Follow-Up
Wyman-Chick, 2016,18 USA10 studies, including randomized (i.e., RCTs) and non-randomized comparative studies (i.e., convenience samples)831 patients with PD (439 who underwent bilateral STN-DBS, 392 non-surgical patients)Bilateral STN-DBS, medication onlyVerbal fluency via ascertaining letter fluency and category fluency scores, follow-up range: 3 to 36 months
Xie, 2016a,20 China10 studies, including 3 RCTs and 7 non-randomized controlled trials797 patients with PD (414 who underwent bilateral STN-DBS, 383 non-surgical patients)Bilateral DBS, medication only (i.e., “dopaminergic drugs or dopamineagonist, such as Madopar, Sinemet, pergolide, ropinirole, and pramipexole instead of STN DBS”)Global cognition using MMSE and MDRS; memory using Digital Span Backward, paired associate learning, RAVLT-total, and RAVLT-delayed recall; verbal fluency via phonemic and semantic fluency; executive function using Raven’s Coloured Matrices, Stroop Color Word Test, Boston naming, Trail Making a and Trail Making b, follow-up range: 6 to 24 months
Xie, 2016b,19 China16 RCTs; 8 relevant studies for the report2,186 patients with PD; 1,347 patients relevant to the reportAmong the relevant studies:
Bilateral GPi-DBS, BMT (3 studies)
STN-DBS, BMT (5 studies; 4 bilateral; 1 unspecified)		UPDRS (depending on primary study, whole score and subscores, stimulation on, and sometimes off), PDQ-39, LED, follow-up range: 6 months to 5 years

BMT = best medical therapy; DBS = deep brain stimulation; GPi = globus pallidus interna; LED= levodopa-equivalent dose; MDRS = Mattis Dementia Rating Scale; MMSE = Mini Mental State Examination; PDQ-39 = Parkinson’s Disease Questionnaire 39 items; RCT = randomized controlled trial; RAVLT-total = Rey Auditory Verbal Learning Test-total; STN = subthalamic nucleus; UPDRS =Unified Parkinson’s Disease Rating Scale; USA = United States of America

From: Deep Brain Stimulation for Parkinson’s Disease: A Review of Clinical Effectiveness, Cost-Effectiveness, and Guidelines

Cover of Deep Brain Stimulation for Parkinson’s Disease: A Review of Clinical Effectiveness, Cost-Effectiveness, and Guidelines
Deep Brain Stimulation for Parkinson’s Disease: A Review of Clinical Effectiveness, Cost-Effectiveness, and Guidelines [Internet].
Lachance C, Spry C, MacDougall D.
Copyright © 2018 Canadian Agency for Drugs and Technologies in Health.

The copyright and other intellectual property rights in this document are owned by CADTH and its licensors. These rights are protected by the Canadian Copyright Act and other national and international laws and agreements. Users are permitted to make copies of this document for non-commercial purposes only, provided it is not modified when reproduced and appropriate credit is given to CADTH and its licensors.

Except where otherwise noted, this work is distributed under the terms of a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International licence (CC BY-NC-ND), a copy of which is available at http://creativecommons.org/licenses/by-nc-nd/4.0/

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.